Rosuvastatin's expanded indication draws criticism
April 15th 2010Following FDA?s expanded indication for rosuvastatin (Crestor, AstraZeneca) in February, the drug?s producer now plans to extend the market for the drug by offering it as a preventive measure to people who do not have cholesterol issues.
Liraglutide may improve glycemic control in patients with type 2 diabetes
April 15th 2010Patients taking oral antidiabetes drugs who switched from exenatide twice daily to liraglutide once daily experienced further reductions in hemoglobin A1c and weight loss, according to the results of a clinical study.
Global TB collaboration pushes to generate more effective disease-fighting regimens
April 15th 2010FDA Commissioner Margaret Hamburg, MD, addressed health leaders worldwide who represent industry, academia, government, and advocacy to help kick off a global consortium to fight tuberculosis (TB). She recently spoke at a press conference in Washington.
Pharmacist intervention boosts patient compliance
April 7th 2010While approximately 40% of patients with schizophrenia have been partly or entirely nonadherent with antipsychotic medications, patient adherence improved dramatically when Veterans Affairs pharmacy staff coordinated these patients' medications, according to a new study.
Investigational drug may boost survival for certain prostate cancer patients
March 15th 2010Cabazitaxel, an investigational compound under development by Sanofi-aventis, plus prednisone/prednisolone, is associated with overall survival and progression-free survival in patients with metastatic (advanced) hormone-refractory prostate cancer whose disease advanced after treatment with docetaxel-based chemotherapy.
RPh second victim in Ohio drug error
January 15th 2010A webinar examining the pharmacy error that led to the death of a two-year-old girl and the conviction of an Ohio pharmacist criticized the legal system for criminalizing the event as well as the flawed hospital procedures that prevented discovery of the pharmacy tech's fatal error.